Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B), while iShares 10 20 Year Treasury Bond ETF trades at $92.11 (market cap $11.02B). The key difference: Halozyme Therapeutics Inc. Common Stock and iShares 10 20 Year Treasury Bond ETF are close in size by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| HALO | TLH | |
|---|---|---|
Market Cap | $12.58B | $11.02B |
Volume | 2,179,278 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $115.22 | $105.36 |
52-Week Low | $61.63 | $91.34 |
Typical Hold Time | 1 Days | 60 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $91.45, down 0.12% with a bearish technical outlook. The ETF has seen unusually high trading volume recently, with 2.3 million shares traded on September 30, 2026. Bond market volatility has driven significant price movements as 10-year Treasury yields reached multi-decade highs above 5% before pulling back. The fund maintains regular dividend distributions, with recent payments ranging from $0.36 to $0.38 per share.
The outlook remains challenging amid persistent bond market volatility and expectations of higher-for-longer interest rates. Rising yields pressure bond prices, creating headwinds for TLH, though current levels may attract income-seeking investors. Key risks include further Fed tightening and inflation concerns, while potential catalysts include economic slowdown or Fed policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
